Skip to main content

Table 2 Univariate Predictors of Inotrope Use

From: Predictors of inotrope use in patients undergoing concomitant coronary artery bypass graft (CABG) and aortic valve replacement (AVR) surgeries at separation from cardiopulmonary bypass (CPB)

 

Inotropic support group(n = 50)

Noninotropic support group(n = 47)

P value

Age (≥ 70 years)

31 (32%)

18 (19%)

0.02

Sex

   

   Male

24(25%)

19(20%)

0.43

   Women

26(27%)

28(29%)

 

BMI ≥ 30

28(29%)

14(14%)

0.04

Diabetes Mellitus

21(22%)

25(26%)

0.61

CKD stage 3–5 (GFR<60 mL/min/1.73 m2)

14(14%)

5(5%)

0.02

Pulmonary hypertension

18(19%)

15(15%)

0.69

LVEF ≤ 40%

45(46%)

31(32%)

0.001

LVH

36(37%)

43(44%)

0.11

Moderate to severe MR

21(22%)

15(15%)

0.37

Wall motion abnormalities

16(16%)

14(14%)

0.86

Drop of hemoglobin ≥ 6 gm/dl

29(30%)

16(16%)

0.02

Pre-operative use of beta blocker

26(27%)

31(32%)

0.23

LVEDP ≥ 20 mm Hg

45(46%)

31(32%)

0.006

CI ≤ 2.5 L/min/m2

29(30%)

15(15%)

0.001

  1. Abbreviations: BMI, body mass index; CKD, chronic kidney disease; MR, mitral regurgitation; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LVEDP, left ventricular end diastolic pressure; CI, cardiac index